autoantigen trim21ro52 as a possible target for treatment of systemic lupus erythematosus自身抗原trim21ro52作为一个可能的目标治疗系统性红斑狼疮.pdfVIP

Hindawi Publishing Corporation International Journal of Rheumatology Volume 2012, Article ID 718237, 11 pages doi:10.1155/2012/718237 Review Article Autoantigen TRIM21/Ro52 as a Possible Target for Treatment of Systemic Lupus Erythematosus Ryusuke Yoshimi,1 Yoshiaki Ishigatsubo,1 and Keiko Ozato2 1 Department of Internal Medicine and Clinical Immunology, Yokohama City University Graduate School of Medicine, Yokohama 236-0004, Japan 2 Program in Genomics of Diff erentiation, National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, MD 20892, USA Correspondence should be addressed to Ryusuke Yoshimi, yoshiryu@med.yokohama-cu.ac.jp Received 11 January 2012; Revised 1 April 2012; Accepted 2 April 2012 Academic Editor: Javier Martin Copyright © 2012 Ryusuke Yoshimi et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Systemic lupus erythematosus (SLE) is a chronic, systemic, and autoimmune disease, whose etiology is still unknown. Although there has been progress in the treatment of SLE through the use of glucocorticoid and immunosuppressive drugs, these drugs have limited efficacy and pose significant risks of toxicity. Moreover, prognosis of patients with SLE has remained difficult to assess. ¨ TRIM21/Ro52/SS-A1, a 52-kDa protein, is an autoantigen recognized by antibodies in sera of patients with SLE and Sjogren’s syndrome (SS), another systemic autoimmune disease, and anti-TRIM21 antibodies have been used as a diagn